Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...
Raj Indupuri, CEO, eClinical Solutions, touched on how AI can significantly enhance risk identification and mitigation in clinical trials by enabling integrated, data-driven quality management from ...
Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...
In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...
PE: How long will it take for the market to be impacted by FDA's ANDA Prioritization Pilot? Botha: It’s a relative window. It ...
Manifold Bio announced a strategic research collaboration and license agreement with Roche, aiming to apply Manifold's tissue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback